Response definitions and European Leukemianet Management recommendations

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 331-341

  Baccarani, Michele ^a   Castagnetti, Fausto ^a   Gugliotta, Gabriele ^a   Palandri, Francesca ^a   Soverini, Simona ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

chronic myeloid leukaemia; European leukemianet; Prognosis; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IC 50; METAPHASE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

DRUG MONITORING; EUROPE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 71849109054     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.10.001     Document Type: Review

References (79)

1. O'Brien S.G., Guilhot F., Larson R., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
2. Hughes T.P., Kaeda J., Brandford S., et al. Frequency of major molecular response to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1421-1432
3. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
4. Jabbour E., Cortes J.E., Giles F., et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 109 (2007) 2171-2181
5. Hehlmann R., and Hochhaus A. Baccarani M on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet 370 (2007) 342-350
6. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (2008) 4808-4815
7. Talpaz M., Shah P.S., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
8. Guilhot F., Apperley J., Kim D.W., et al. Dasatinib induces significant hematologic and cytogenetic response in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
9. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (2007) 3207-3213
10. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
11. Hochhaus A., Baccarani M., Deininger M., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22 (2008) 1200-1206
12. Shah N.P., Kantarjian H.M., Kim D.W., et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib -resistant and intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26 (2007) 1-9
13. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
14. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2008) 3540-3546
15. Le Coutre P., Ottmann O.G., Giles F., et al. Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is a active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111 (2008) 1834-1839
16. Deininger M.W. Nilotinib. Clin Cancer Res 14 (2008) 4027-4031
17. Reinhold U., Henning E., Leiblein S., et al. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white bone marrow cells in CML patients treated with imatinib. Leukemia 17 (2003) 1925-1929
18. Raanani P., Ben-Bassat I., Gan S., et al. Assessment of the response to imatinib in chronic myeloid leukemia patients: comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol 73 (2004) 243-250
19. Testoni N, Marzocchi G, Luatti S, et al. A prospective study in Ph+ chronic myeloid leukemia (CML) patients showing that interphase fluorescence-in-situ- hybridization (I-FISH) is effective as conventional cytogenetics for definition of cytogenetic response to imatinib. Correlation with molecular response (a GIMEMA CML WP study). Haematologica. in press.
20. Hughes T., Deininger M., Hocchaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
21. Saldanha J., Silvy M., Beaufils N., et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia 21 (2007) 1481-1487
22. Müller M.C., Erben P., Saglio G., et al. Harmonization of a BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22 (2008) 96-102
23. Branford S., Fletcher L., Cross N.C.P., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112 (2008) 3330-3337
24. Jones D., Kamel-Reid S., Bahler D., et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia. J Mol Diagn 11 (2009) 4-11
25. Kantarjian H.M., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108 (2006) 1835-1840
26. Druker B.J., Guilhot F., O'Brien S.O., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
27. De Lavallade H., Apperley J.F., Khorashad J., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26 (2008) 3358-3363
28. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, in press.
29. O'Brien S.G., Guilhot F., Goldman J., et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112 11 (2008) 76 Abstract N. 186
30. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112 (2008) 4437-4444
31. Roy L., Guilhot J., Krahnke T., et al. Survival advantage from imatinib compared with the combination interferon-alfa plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108 (2006) 1478-1484
32. Hughes T., Hochhaus A., Branford S., et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients with chronic phase chronic myeloid leukemia (CML-CP). Blood 112 11 (2008) 129-130 Abstract No. 334
33. Hughes T., Branford S., While D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112 (2008) 3965-3972
34. Müller M.C., Hanfstein B., Erben P., et al. Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia - an interim analysis of the randomized German CML study IV. Blood 112 11 (2008) 129 Abstract No. 333
35. Branford S., Lawrence R., Grigg A., et al. Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response. Blood 112 11 (2008) 735-736 Abstract No. 2113
36. Press R.D., Galderisi C., Yang R., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 13 20 (2007) 6136-6143
37. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 112 (2008) 837-845
38. Kantarjian H.M., Shan J., Jones D., et al. Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR). Blood 112 11 (2008) 169-170 Abstract No. 445
39. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 8 (2007) 1018-1029
40. Apperley J.F. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007) 1116-1129
41. Quintas-Cardama A., and Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 113 (2009) 1619-1630
42. O'Hare T., Eide C.A., and Deininger M.W.N. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110 (2007) 2242-2249
43. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 12 (2006) 7374-7379
44. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
45. Khorashad J.S., de Lavallade H., Apperley J.F., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26 (2008) 4806-4813
46. Soverini S., Colarossi S., Gnani A., et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92 (2007) 401-403
47. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63 (1984) 789-799
48. Hasford J., Pfirmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90 (1998) 850-858
49. Jabbour E., Kantarjian H.M., Jones D., et al. Imatinib mesylate dose escalation is associated with durable response in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113 (2009) 2154-2160
50. Cortes I, Kantarjian H, Goldberg S, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol, in press.
51. Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase II trial of the Gimema CML WP. Blood, in press.
52. Cortes J., Baccarani M., Guilhot F., et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (tyrosine kinase inhibitor optimization and selectivity) study. Blood 112 11 (2008) 130-131 Abstract No. 325
53. Baccarani M., Rosti G., Castagnetti F., et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukemia. A European LeukemiaNet study. Blood 113 (2009) 4497-4504
54. Guilhot F., Mahon F.X., Guilhot J., et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML Group (FI LMC). Blood 112 11 (2008) 74 Abstract No. 183
55. Hehlmann R., Saussele S., Lauseker M., et al. Randomized comparison of imatinib 400 mg vs. imatinib + IFN vs. imatinib + araC vs. imatinib after IFN vs. imatinib 800 mg: optimized treatment and survival. Designed first interim analysis of the German CML study IV. Blood 112 11 (2008) 75 Abstract No. 184
56. Burgess M., Skaggs B.J., Shah N.P., et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. PNAS 102 (2005) 3395-3400
57. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell. 7 (2005) 129-141
58. Golemovic M., Verstovsek S., Giles F., et al. AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 11 (2005) 4941-4947
59. Shah N., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
60. Tokarski J.S., Newitt J.A., Chang C.Y.J., et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutation. Cancer Res. 66 (2006) 5790-5797
61. Baccarani M., Rosti G., Saglio G., et al. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 112 11 (2008) 172 Abstract No. 450
62. Hochhaus A., Müller M., Radich J., et al. Dasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinib. Blood 112 11 (2008) 400 Abstract No. 1095
63. Kantarjian H.M., Kim D.W., Dorlhiac-Llacer P., et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035. Blood 112 11 (2008) 1106-1107 Abstract No. 3224
64. Hochhaus A, Müller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, in press.
65. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112 (2008) 516-517
66. Milojkovic D., Bua M., Apperly J.F., et al. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival. Blood 112 11 (2008) 129 Abstract No. 332
67. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2 (2002) 117-125
68. Corbin A.S., La Rosee P., Stoffregen E.P., et al. Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
69. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112 (2003) 831-843
70. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity oof BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistance ABL kinase domain mutants. Cancer Cell. 65 (2005) 4500-4505
71. Manley P.W., Cowan-Jacob S.W., and Mestan J. Advances in the structural biology, design and clinical development of BCR-ABL kinase inhibitors for the treatment of chronic myeloid leukemia. Biophys Acta 1754 (2005) 3-13
72. Bradeen H.A., Eide C.A., O'Hare T., et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108 (2006) 2332-2338
73. Ray A., Cowan-Jacob S.W., Manley P.W., et al. Indentification of BCR-ABL point mutations conferring resistance to the ABL kinase inhibitor AMN107 (nilotinib) by random mutagenesis study. Blood 109 (2007) 5011-5015
74. Redaelli S., Piazza R., Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27 (2009) 469-471
75. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients whith chronic myeloid leukaemia before allogeneic blood or marrow transplantation: cronic leukemia working party of the European group for blood and marrow transplantation. Lancet 352 (1998) 1087-1092
76. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). l. Haematologica 91 4 (2006) 513-521
77. Saussele S., Lauseker M., Gratwohl A., et al. Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: high survival rate following allogeneic HSCT after imatinib failure: results of the German CML study IV. Blood 112 11 (2008) 171 Abstract No. 448
78. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia. An update of concepts and management recommendations of European Leukemianet. J Clin Oncol., in press.
79. Baccarani M., Pane F., and Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 92 (2008) 161-169